The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.61 is in distress zone. This implies bankruptcy possibility in the next two years.
China Resources Pharmaceutical Group has a Altman Z-Score of 1.62, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
China Resources Pharmaceutical Group (STU:640) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Altman Z-Score Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's Altman Z-Score falls into.
China Resources Pharmaceutical Group Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
China Resources Pharmaceutical Group (STU:640) has a Altman Z-Score of 1.62 as of Jul. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on China Resources Pharmaceutical Group and its competitors. This is near median its historical median of 1.63. Over the past decade, China Resources Pharmaceutical Group's Altman Z-Score has ranged from 1.36 to 2.03. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #701 out of 951 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is China Resources Pharmaceutical Group's Altman Z-Score too high?
China Resources Pharmaceutical Group's current Altman Z-Score of 1.62 is near median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 2.03. The Drug Manufacturers industry median Altman Z-Score is 3.23. China Resources Pharmaceutical Group's value of 1.62 is 49.8% below this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #701 out of 951 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #701 out of 951 companies for Altman Z-Score. This places China Resources Pharmaceutical Group in the lower half of its industry. The industry median Altman Z-Score is 3.23. China Resources Pharmaceutical Group's value of 1.62 is 49.8% below this benchmark. Historically, China Resources Pharmaceutical Group's own Altman Z-Score has ranged from 1.36 to 2.03 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 3.23, China Resources Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.23, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current Altman Z-Score of 1.62 is 49.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current Altman Z-Score is 1.62, which is near median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.49 — trading 24.1% below its estimated fair value. The current Altman Z-Score is 1.62, which is near median its 10-year median of 1.63 and 49.8% below the Drug Manufacturers industry median of 3.23. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Altman Z-Score is 1.62 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.49 is trading 24.1% below its estimated GF Value™ of €0.64.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
Altman Z-Score: 1.62 (near median its 10-year median of 1.63)
GF Value™: €0.64 vs. price of €0.49 (24.1% below fair value)
Industry Position: 49.8% below the Drug Manufacturers median (#701 of 951)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score
Get the complete analysis for STU:640
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
